Manfred Horst is a Director Business Development Europe and working from an office at MSD France, the French affiliate of MSD which has its HQ in New Jersey (and is known as Merck & Co. in the US). MSD is one of the biggest pharmaceutical companies in the world with a 2014 revenue of €37.4Bn and €6.4Bn research expenditure. It also has a surprisingly long and rich history, starting back in 1861 Germany.
MSD researchers have been responsible for the discovery of many new medicines (e.g. the first statin to treat high cholesterol, the first diuretic to treat hypertension and heart failure, the first antibiotic against tuberculosis…) and vaccines (e.g. MMR for babies and the HPV for cervical cancer etc.). Now, Oncology is one of this biotech’s biggest priorities.
Manfred covers Germany (his native country), France, Italy, Switzerland, Israel and Russia as a licensing “scout”. This means he is looking for interesting molecules and technologies which have the potential to become important new medicines or vaccines.
What is your background?